Melanoma and nanotechnology-based treatment

The malignant tumor known as melanoma is generated from melanocytes in the epidermis basal layer1. The main forms of treatment for melanoma now accessible are surgery, radiation, systemic therapy, adjuvant therapy, photodynamic therapy, and transfer to therapy for mucosal melanoma2. Typical surgical treatments include biopsies, enlarged resections, sentinel lymph node biopsies, lymph node dissections, and in-transit metastases (for individuals with stage III illness). The main variables that affect adjuvant therapy for melanoma are the clinical stage and patient risk level3. There is still disagreement over the appropriate adjuvant treatment for patients with very high risks, despite the fact that there is currently widespread consensus regarding the optimal adjuvant therapy for individuals with low, medium, and high risks. For certain melanoma types, various strategies and tailored care should be used. Adjuvant treatment with interferon therapy is essential for those at high risk. There are two types of melanomas radiotherapy: adjuvant and palliative radiotherapy. Moreover, internal medicine-based systemic therapy is often utilized in patients with metastatic melanoma, characterized by a poor prognosis and a lack of curative therapies. Recent developments in immunotherapies and customized, targeted medicines have improved patient outcomes for people with metastatic melanoma. Over the last few decades, nanotechnology has seen significant advancement3,4, particularly its use in medicine5,6. Nano-agents provide innovative techniques for treating several ailments because of their distinctive capacities to improve medicine delivery. For instance, standard chemotherapy drugs used to treat cancer may not effectively target the tumor. They may also negatively affect healthy cells in the body, creating many issues and adversely affecting the patient's quality of life. As an alternative, nanotechnology may be used to provide personalized drug delivery, enhancement of pharmacokinetics, and get rid of these barriers7,8. Many cancer types have benefited from using nanomaterials such as DDSs, and melanoma detection and treatment using nanotechnology have also been proposed and investigated. Targeted drugs encased in nanoparticles or laden with them might easily breach the biological barrier and be given particularly to melanoma cells, where they may do their destructive spell. Nanomaterials' dimensions and surface characteristics are to blame for this. Second, by reducing the unfavorable effects of off-target tissue toxicity, nanomaterials may improve pharmaceutical efficacy. Moreover, nanosystems may reduce drug clearance, halt the body from degrading drugs that have been loaded, and lengthen the drug's half-life, permitting dosage decreases9. Many nanosystems, such as lipid systems, inorganic nanoparticle systems, natural nanosystems, and polymeric systems, have been used in the detection and therapy of melanoma. For instance, lipid nanosystems, including liposomes, nanoemulsions, and solid lipid nanoparticles, have been created, whereas typical inorganic nanoparticle systems like AuNPs, SiNPs, copper nanoparticles, and nanotubes are also prevalent. Natural nanosystems such as exosomes, polymeric micelles, hydrogels, nanospheres, dendritic macromolecules, and polymeric nanoparticles are examples of polymerization systems10. Lipid systems perform better in terms of physical stability and controlled release, and compared to other nanoparticle systems, biocompatibility. These lipid systems also often have minimal side effects, can be broken down by the body, and have a high level of physical stability. Lipid systems, including liposomes, nanoemulsions, and solid lipid nanoparticles, have undergone extensive investigation to treat clinical problems11. Liposomes are a kind of double nanoparticle used in cancer therapy because of their advantageous pharmacokinetic characteristics. Liposomes have also been shown to increase the efficacy of drugs used to treat melanoma, particularly those that target the cell cycle, using paclitaxel. The corpuscle sheath package (consisting of sphingomyelin and cholesterol) of liposomes of vincristine, according to Bedikian et al., improved circulatory half-life, gathered around the tumor's location, and increased therapeutic effectiveness, enabling better outcomes without modifying drug dose. In addition to that, Matsumoto et al. showed that the use of cationic liposomes containing the human interferon B (HuIFNb) gene (IAB-1) was superior to the use of HuIFNb protein in the treatment of melanoma because it had better anticancer efficacy11,12. Melanoma vaccines that will both cure and prevent the illness may potentially be developed using liposomes. Gargett et al.13 conducted research on Lipovaxin-MM, an intravenous multicomponent dendritic cell-targeted vaccination used to treat metastatic melanoma. Over the 12-week trial period, Lipovaxin-MM was shown to be well tolerated without appreciable immunogenicity or therapeutic toxicity, and early results suggested that Lipovaxin-MM might be effective as an immunotherapy for melanoma. Cancer vaccines, which have been widely explored in basic and clinical trials, differ from other vaccinations in that they employ subunit antigens, and they have a rather straightforward chemical structure, manufacturing procedure, and storage need. Yet given the complexity of the tumor microenvironment, particularly in more advanced tumor models, other approaches could be required to provide therapeutic effects14. Simultaneous drug administration and imaging are possible using inorganic nanoparticles with strong biocompatibility, such as silica, gold, copper, and nanotubes15. Yet, since these nanoparticles may not be able to precisely target the affected location, they typically need to be coupled with additional ligands that target. For instance, titanium dioxide is a weak, dark-suited nanocrystal material with photocatalytic activity. There are fewer uses for neat TiO2 in photodynamic treatment since it is exclusively photoactive in the UV range. Kozinska et al. showed that new inorganic nanoparticles might kill melanoma cells by photodynamic methods by using fullerenes with functionalities and TiO2 with a modified surface used as a photosensitizer to cure melanoma. It has been shown that this novel inorganic TiO2 nanoparticle combination has a longer retention duration in vivo, is nontoxic, and is stable in the absence of light irradiation. In a mouse melanoma model, Ferreira et al. evaluated the functionalization of europium (III)-yttrium vanadate nanoparticles with 3-chloropropyl-trimethoxysilane and folic acid. The modified cisplatin nanoparticles, whether they contained folic acid or not, showed potent antitumor effects in comparison to cisplatin alone16. Sapino et al. developed an inorganic nanoparticle system comprising mesoporous silica nanoparticles with aminopropyl-functionalization to administer quercetin topically (NH2-MSNs). They then looked at how this system influenced JR8 human melanoma cell growth and found that these NH2-MSNs had strong antiproliferative effects17. Polymeric systems include things like hydrogels, dendrimers, micelles, and polymeric nanoparticles. The manufacture of these polymeric nanosystems is simpler than that of iodinated nanosystems, which overcomes the latter's shortcomings of high viscosity and restricted application. Polymeric nanosystems, such as liposome systems, may enhance computed tomography imaging of tumors and provide effective targeted therapy for melanoma18. While polymeric systems exist in a variety of shapes and, like other nanoplatforms, have excellent capacities for delivering nano-drugs, certain polymeric nanoparticle systems have limited physical stability and substantial toxicity, which precludes their use in clinical settings19. Clinical responses to the most recent melanoma therapies are at their peak. Nanotechnology has made it feasible to create smaller, safer, and more precise DDSs. As part of cutting-edge treatment methods, more and more melanoma drugs are contained within nanocapsules. The therapeutic efficiency of the drugs given to melanoma patients is therefore projected to be improved by nano DDSs. Upcoming research challenges mainly revolve around a better comprehension of the mechanisms that offer nanosystems for treating melanoma an edge over traditional drug formulations. Nano DDSs provide a wide variety of uses for detecting and treating melanoma, especially metastatic melanoma, because of their exceptional properties, like enhanced histocompatibility, improved drug targeting, lower toxicity, and many others.